Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PD-1 mAb Therapy Alone or With Metabolic Modulators in Solid Tumor Malignancies
NCT04114136Phase 2Recruiting
- Start
- Sep 2020
- Primary completion
- Apr 2032
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of liquid metformin (Aspargo Labs), rosiglitazone in melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), microsatellite instability-high cancer. Started Sep 2020; status: recruiting.
02
Drugs
liquid metformin (Aspargo Labs)rosiglitazone
03
Conditions
melanomarenal cell carcinoma (RCC)non-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)microsatellite instability-high cancer
Beyond the preview
Go deeper on NCT04114136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04114136.